Furthermore, ANLN was identified as a prognostic biomarker and an increase in ANLN mRNA from normal tissue to malignant disease was observed in breast [9], lung [11], bladder [12,13], gastric [14], colorectal [15], nasopharyngeal [16] and pancreatic cancer [17]. The gene discussed is ANLN; the disease is familial pancreatic carcinoma.